Study of Sacituzumab Govitecan in Patients With Solid Tumor
The goal of this study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with solid tumor.
Solid Tumor
DRUG: Sacituzumab Govitecan-hziy
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment, ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR)., Up to 4 years
Duration of Response (DOR), DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of definitive progressive disease (PD) or death from any cause (whichever comes first)., Up to 4 years|Disease Control Rate (DCR), DCR is defined as the proportion of participants who achieve CR, PR, or stable disease (SD)., Up to 4 years|Progression-free Survival (PFS), PFS is defined as the time from the first dose of sacituzumab govitecan-hziy (SG) until the date of objective PD, or death (whichever comes first)., Up to 4 years|Overall Survival (OS), OS is defined as the time from the first dose of SG until death due to any cause., Up to 4 years|Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, First dose date up to 4 years plus 30 days|Percentage of Participants Experiencing Serious Adverse Events (SAEs) According to NCI CTCAE Version 5.0, First dose date up to 4 years plus 30 days|Pharmacokinetic (PK) Parameter: Cmax of Sacituzumab Govitecan-hziy and Free SN-38, Cmax is defined as the maximum observed concentration of drug., Up to 4 years|PK Parameter: Tmax of Sacituzumab Govitecan-hziy and Free SN-38, Tmax is defined as the time (observed time point) of Cmax., Up to 4 years|PK Parameter: Ctrough of Sacituzumab Govitecan-hziy and Free SN-38, Ctrough is defined as the concentration of drug at the end of the dosing interval., Up to 4 years|Percentage of Participants Who Developed Anti-Drug Antibodies (ADAs) Against SG, Up to 4 years
Only Cohort C: Cervical Cancer (CC) is enrolling at this time.